Medical Disclaimer: This article is for educational purposes only and does not constitute medical advice. Always consult a qualified healthcare provider before making any changes to your treatment plan. Do not discontinue prescribed medications without physician supervision.
Of all the therapeutic applications of cannabinoids, epilepsy has the strongest clinical evidence base. The FDA approval of Epidiolex — a purified CBD formulation — for two rare forms of childhood epilepsy marked a historic moment: the first cannabis-derived pharmaceutical approved in the United States. But the science extends well beyond that single approval, and understanding it is essential for anyone exploring cannabinoids as part of a comprehensive epilepsy management approach.
The Endocannabinoid System and Seizure Activity
The endocannabinoid system plays a critical role in regulating neuronal excitability — the balance between excitatory and inhibitory signaling in the brain that, when disrupted, produces seizures. CB1 receptors are among the most densely expressed receptors in the brain, concentrated in regions directly involved in seizure generation and propagation including the hippocampus, cortex, and basal ganglia.
Endocannabinoids act as retrograde neurotransmitters — they are released by postsynaptic neurons and travel backward across the synapse to suppress excessive presynaptic activity. This “on-demand” inhibitory mechanism is one of the brain’s primary defenses against runaway excitation. In epilepsy, this system is often dysregulated, and cannabinoids may help restore its function.
CBD and Epilepsy: The Clinical Evidence
FDA-Approved Epidiolex
In 2018, the FDA approved Epidiolex (pharmaceutical-grade CBD) for Dravet syndrome and Lennox-Gastaut syndrome — two severe, treatment-resistant forms of childhood epilepsy. The approval was based on three randomized, double-blind, placebo-controlled clinical trials:
- A 2017 New England Journal of Medicine study found that CBD reduced convulsive seizure frequency by 38.9% compared to 13.3% for placebo in Dravet syndrome patients
- Two Lennox-Gastaut trials showed significant reductions in drop seizure frequency (41.9% and 37.2% reduction vs. placebo)
- A meaningful percentage of patients in all trials achieved ≥50% reduction in seizure frequency — considered a clinically significant response
Beyond Dravet and Lennox-Gastaut
Research and clinical experience suggest CBD’s anticonvulsant effects extend to other epilepsy types. A 2018 retrospective study in Epilepsy & Behavior found that 39% of patients with various epilepsy types reported ≥50% seizure reduction with CBD use. A 2019 study in the Journal of the American Medical Association found that 89% of children with epilepsy whose parents reported CBD use experienced some reduction in seizure frequency.
How CBD Produces Anticonvulsant Effects
CBD’s anticonvulsant mechanisms are distinct from traditional antiepileptic drugs and involve multiple pathways:
- GPR55 antagonism — GPR55 is a receptor that, when activated, promotes neuronal excitability. CBD blocks GPR55, reducing excitatory signaling
- TRPV1 desensitization — CBD activates and then desensitizes TRPV1 channels, reducing their contribution to excitatory neurotransmission
- Sodium channel modulation — CBD inhibits voltage-gated sodium channels, the same target as many conventional antiepileptic drugs
- Adenosine reuptake inhibition — CBD increases adenosine levels, which has inhibitory effects on neuronal activity
- Anandamide enhancement — by inhibiting FAAH, CBD increases endogenous anandamide, which activates CB1 receptors and suppresses excitatory neurotransmission
CBG and Neurological Support
While CBD has the strongest evidence base for epilepsy specifically, CBG’s neuroprotective properties are relevant to the broader neurological picture. CBG has demonstrated the ability to protect neurons from oxidative stress and excitotoxicity — mechanisms that contribute to seizure-related brain damage. For individuals using cannabinoids as part of a comprehensive neurological wellness approach, CBG’s neuroprotective activity complements CBD’s anticonvulsant effects.
Important Considerations
Several critical points for anyone with epilepsy considering cannabinoids:
- Drug interactions — CBD is metabolized by cytochrome P450 enzymes (CYP3A4 and CYP2C19) and can significantly affect the blood levels of many antiepileptic drugs, particularly clobazam and valproate. This interaction requires physician monitoring and potential dose adjustments.
- Do not discontinue medications — Cannabinoids should be considered as complementary to, not a replacement for, prescribed antiepileptic therapy without physician guidance
- THC considerations — THC can be proconvulsant in some individuals and should be avoided by people with epilepsy. THC-free CBD products are essential for this application
- Dose matters — The doses used in clinical trials (typically 10–20mg/kg/day) are significantly higher than typical wellness doses. Work with a physician to determine appropriate dosing
CBD Wellness Products for Neurological Support
For individuals exploring cannabinoids for neurological wellness support, CBD Wellness offers THC-free options through our cbdDR line — independently verified to contain no detectable THC. All products are third-party lab tested. View our lab results here.
We strongly recommend consulting with a neurologist or epilepsy specialist before incorporating any cannabinoid product into an epilepsy management plan.